Clinical and Immunologic Profiles in Incomplete Lupus Erythematosus and Improvement with Hydroxychloroquine Treatment

Overview

Journal Autoimmune Dis

Publisher Wiley

Date 2017 Jan 25

PMID 28116147

Citations 19

Authors

Nancy J Olsen

Carl McAloose

Jamie Carter

Bobby Kwanghoon Han

Indu Raman

Quan-Zhen Li

Duanping Liao

Affiliations

Soon will be listed here.

Abstract

. The study goals were to evaluate performance of SLE classification criteria, to define patients with incomplete lupus erythematosus (ILE), and to probe for features in these patients that might be useful as indicators of disease status and hydroxychloroquine response. . Patients with ILE ( = 70) and SLE ( = 32) defined by the 1997 American College of Rheumatology criteria were reclassified using the 2012 Systemic Lupus International Collaborating Clinics criteria. Disease activity, patient reported outcomes, and levels of Type I interferon- (IFN-) inducible genes, autoantibodies, and cytokines were measured. Subgroups treated with hydroxychloroquine (HCQ) were compared to patients not on this drug. . The classification sets were correlated ( = 0.87). ILE patients were older ( = 0.0043) with lower disease activity scores ( < 0.001) and greater dissatisfaction with health status ( = 0.034) than SLE patients. ILE was associated with lower levels of macrophage-derived cytokines and levels of expressed Type I IFN-inducible genes. Treatment of ILE with HCQ was associated with better self-reported health status scores and lower expression levels of Type I IFN-inducible genes than ILE patients not on HCQ. . The 2012 SLICC SLE classification criteria will be useful to define ILE in trials. Patients with ILE have better health status and immune profiles when treated with HCQ.

Citing Articles

Environment and systemic autoimmune rheumatic diseases: an overview and future directions.

Choi M, Costenbader K, Fritzler M Front Immunol. 2024; 15:1456145.

PMID: 39318630 PMC: 11419994. DOI: 10.3389/fimmu.2024.1456145.

Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.

Rodriguez-Carrio J, Burska A, Conaghan P, Dik W, Biesen R, Eloranta M RMD Open. 2023; 9(1).

PMID: 36882218 PMC: 10008483. DOI: 10.1136/rmdopen-2022-002864.

Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.

Burska A, Rodriguez-Carrio J, Biesen R, Dik W, Eloranta M, Cavalli G RMD Open. 2023; 9(1).

PMID: 36863752 PMC: 9990675. DOI: 10.1136/rmdopen-2022-002876.

Genetic load in incomplete lupus erythematosus.

Slief M, Kheir J, Smith M, Mowery C, Macwana S, DeJager W Lupus Sci Med. 2023; 10(1.

PMID: 36599633 PMC: 9815005. DOI: 10.1136/lupus-2022-000843.

Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial.

Balevic S, Randell R, Weiner D, Beard C, Schanberg L, Hornik C Lupus Sci Med. 2022; 9(1).

PMID: 36328395 PMC: 9639143. DOI: 10.1136/lupus-2022-000811.

References

Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

Olsen N, Yousif M, Mutwally A, Cory M, Elmagboul N, Karp D . Organ damage in high-risk patients with systemic and incomplete lupus syndromes. Rheumatol Int. 2013; 33(10):2585-90. PMC: 4429789. DOI: 10.1007/s00296-013-2783-3. View

Olsen N, Spurlock 3rd C, Aune T . Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther. 2014; 16(1):R17. PMC: 3978848. DOI: 10.1186/ar4444. View

Clancy R, Markham A, Buyon J . Endosomal Toll-like receptors in clinically overt and silent autoimmunity. Immunol Rev. 2015; 269(1):76-84. PMC: 4685960. DOI: 10.1111/imr.12383. View

Graeber K, Olsen N . Th17 cell cytokine secretion profile in host defense and autoimmunity. Inflamm Res. 2011; 61(2):87-96. DOI: 10.1007/s00011-011-0419-1. View

Pan H, Leng R, Li X, Zheng S, Ye D . Targeting T-helper 9 cells and interleukin-9 in autoimmune diseases. Cytokine Growth Factor Rev. 2014; 24(6):515-22. DOI: 10.1016/j.cytogfr.2013.09.001. View

Costenbader K, Schur P . We need better classification and terminology for "people at high risk of or in the process of developing lupus". Arthritis Care Res (Hoboken). 2014; 67(5):593-6. PMC: 4391980. DOI: 10.1002/acr.22484. View

Wieczorek I, Propert K, Okawa J, Werth V . Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA Dermatol. 2014; 150(3):291-6. DOI: 10.1001/jamadermatol.2013.9026. View

Greer J, Panush R . Incomplete lupus erythematosus. Arch Intern Med. 1989; 149(11):2473-6. View

10.

Ines L, Silva C, Galindo M, Lopez-Longo F, Terroso G, Romao V . Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus.... Arthritis Care Res (Hoboken). 2015; 67(8):1180-5. DOI: 10.1002/acr.22539. View

11.

Lu R, Munroe M, Guthridge J, Bean K, Fife D, Chen H . Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun. 2016; 74:182-193. PMC: 5079766. DOI: 10.1016/j.jaut.2016.06.001. View

12.

Robinson E, Werth V . The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine. 2015; 73(2):326-34. DOI: 10.1016/j.cyto.2015.01.031. View

13.

Li Q, Zhou J, Lian Y, Zhang B, Branch V, Carr-Johnson F . Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin Exp Immunol. 2009; 159(3):281-91. PMC: 2819494. DOI: 10.1111/j.1365-2249.2009.04057.x. View

14.

Bertsias G, Pamfil C, Fanouriakis A, Boumpas D . Diagnostic criteria for systemic lupus erythematosus: has the time come?. Nat Rev Rheumatol. 2013; 9(11):687-94. DOI: 10.1038/nrrheum.2013.103. View

15.

Wandstrat A, Carr-Johnson F, Branch V, Gray H, Fairhurst A, Reimold A . Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmun. 2006; 27(3):153-60. DOI: 10.1016/j.jaut.2006.09.001. View

16.

Fonseca A, Ignez C Gaspar-Elsas M, Land M, de Oliveira S . Comparison between three systems of classification criteria in juvenile systemic lupus erythematous. Rheumatology (Oxford). 2014; 54(2):241-7. DOI: 10.1093/rheumatology/keu278. View

17.

Olsen N, Li Q, Quan J, Wang L, Mutwally A, Karp D . Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res Ther. 2012; 14(4):R174. PMC: 3580568. DOI: 10.1186/ar3927. View

18.

Petri M, Orbai A, Alarcon G, Gordon C, Merrill J, Fortin P . Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-86. PMC: 3409311. DOI: 10.1002/art.34473. View

19.

Pincus T . A multidimensional health assessment questionnaire (MDHAQ) for all patients with rheumatic diseases to complete at all visits in standard clinical care. Bull NYU Hosp Jt Dis. 2007; 65(2):150-60. View

20.

Choi M, Barber M, Barber C, Clarke A, Fritzler M . Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care. Lupus. 2016; 25(8):838-49. DOI: 10.1177/0961203316640367. View